HIMS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HIMS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-24), the Forward Annual Dividend Yield of Hims & Hers Health is 0.00%.
As of today (2024-05-24), the Trailing Annual Dividend Yield of Hims & Hers Health is 0.00%.
Hims & Hers Health's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
For the Household & Personal Products subindustry, Hims & Hers Health's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Hims & Hers Health's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Hims & Hers Health (NYSE:HIMS) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Hims & Hers Health's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Dudum | director, 10 percent owner, officer: Chief Executive Officer | 2269 CHESTNUT STREET, #523, SAN FRANCISCO CA 94123 |
Oluyemi Okupe | officer: Chief Financial Officer | 2269 CHESTNUT ST., #523, SAN FRANCISCO CA 94123 |
Soleil Boughton | officer: See Remarks | 2269 CHESTNUT STREET, #523, SAN FRANCISCO CA 94123 |
Lynne Chou O'keefe | director | 2269 CHESTNUT STREET, #523, SAN FRANCISCO CA 94123 |
Irene Becklund | officer: Interim PFO/PAO | 2269 CHESTNUT ST., #523, SAN FRANCISCO CA 94123 |
Melissa Baird | officer: Chief Operating Officer | 2269 CHESTNUT STREET, #523, SAN FRANCISCO CA 94123 |
David B Wells | director | C/O NETFLIX, INC., 100 WINCHESTER CIRCLE, LOS GATOS CA 95130 |
Alex Bard | director | 2269 CHESTNUT STREET, #523, SAN FRANCISCO CA 94123 |
Ivp Executive Fund Xvi, Llc | 10 percent owner | 3000 SAND HILL ROAD, BUILDING 2, SUITE 2, MENLO PARK CA 94025 |
Jules A. Maltz | director | 3000 SAND HILL ROAD, BUILDING 2, SUITE 250, MENLO PARK CA 94025 |
Christiane Pendarvis | director | 2269 CHESTNUT ST., #523, SAN FRANCISCO CA 94123 |
Michael Chi | officer: Chief Marketing Officer | 2269 CHESTNUT ST., #523, SAN FRANCISCO CA 94123 |
Somesh Dash | 10 percent owner | 3000 SAND HILL ROAD, BUILDING 2, SUITE 250, MENLO PARK CA 94025 |
Jack Abraham | 10 percent owner | 1 LETTERMAN DRIVE, SUITE C3500, SAN FRANCISCO CA 94129 |
Patrick Harrison Carroll | officer: Chief Medicall Officer | 2269 CHESTNUT STREET, # 523, SAN FRANCISCO CA 94123 |
From GuruFocus
By Business Wire • 07-31-2023
By Business Wire • 10-19-2023
By GuruFocus Research • 12-26-2023
By Business Wire Business Wire • 12-20-2022
By GuruFocus Research • 12-05-2023
By Business Wire Business Wire • 03-23-2023
By GuruFocus Research • 12-22-2023
By Business Wire • 08-07-2023
By Business Wire Business Wire • 01-18-2023
By GuruFocus Research • 08-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.